RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Arcus Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.14+0.02 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
Arcus Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other collaboration | $40.00M | $23.00M | $26.00M | $30.00M | $31.00M | $34.00M | $36.00M | $37.00M | $40.00M | $39.00M | $37.00M | $36.00M | 34.2% | +29.0% |
| License and Development Services Revenue | – | – | – | $210.00M | $231.00M | $107.00M | $222.00M | $226.00M | $207.00M | $198.00M | $80.00M | $84.00M | – | – |
| Access rights | – | – | – | – | – | – | – | – | $33.00M | $33.00M | $33.00M | $33.00M | – | – |
| License and R&D services | – | – | – | – | – | – | – | – | $202.00M | $195.00M | $79.00M | $83.00M | – | – |
| R&D services | – | – | – | – | – | – | – | – | $12.00M | $9.00M | $5.00M | $4.00M | – | – |
| Access rights | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Arcus Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.